Business
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial
About this update from Illumina, Inc.
[{"type":"text","content":"T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors","length":97,"tagName":"p","attribs":{}},{"type":"text","content":"Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer","length":66,"tagName":"p","attribs":{}},{"type":"text","content":"Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors","length":72,"tagName":"p","attribs":{}},{"type":"text","content":"FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.","length":626,"tagName":"p"},{"type":"text","content":""We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."","length":503,"tagName":"p"},{"type":"text","content":"Leadership and Board ExpansionAlamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.","length":210,"tagName":"p"},{"type":"image","alt":"Stephen Williams, MD, PhD","displaySize":"","headline":null,"caption":"Stephen Williams, MD, PhD","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/67bd12f0114ecee3d65abea5ad14aa65"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/d60fU3lnCyoNhxKyhgpB0w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNTtjZj13ZWJw/https://media.zenfs.com/en/prnew...